8
Treatment
Figure 2. Second-Line or Greater Treatment
VEGFR TKI
monotherapy
Nivolumab or cabozantinib
Combination
immunotherapy
(e.g., nivolumab/ipilimumab)
VEGFR TKI monotherapy
VEGFR TKI with an immune
checkpoint inhibitor
An alternate VEGFR TKI
as a single agent
Patients on immunotherapy
who experience limited
disease progression
(e.g., one site of progression)
Local therapy (radiation,
thermal ablation, excision)
may be offered, and
immunotherapy
may be continued
First-line Treatment
Received
Second-line Treatment
Options
